Outer membrane vesicles derived from Bordetella parapertussis as an acellular vaccine against Bordetella parapertussis and Bordetella pertussis infection

Vaccine

Volumn 31, Issue 45, 2013, Pages 5262-5268

  Bottero, D ^a   Gaillard, M E ^a   Errea, A ^a   Moreno, G ^a   Zurita, E ^a   Pianciola, L ^b   Rumbo, M ^a   Hozbor, D ^a  

^a UNIVERSIDAD NACIONAL DE LA PLATA   (Argentina)

^b Laboratorio Central Subsecretaría de Salud de Neuquén   (Argentina)

Author keywords

Acellular vaccine; Bordetella parapertussis; Bordetella pertussis; OMVs; Protection; Whooping cough

Indexed keywords

INTERLEUKIN 6; MEMBRANE ANTIGEN; PERTACTIN; PERTUSSIS VACCINE;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL COUNT; BACTERIAL OUTER MEMBRANE; BORDETELLA PARAPERTUSSIS; BORDETELLA PARAPERTUSSIS INFECTION; BORDETELLA PERTUSSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; LUNG CLEARANCE; MEMBRANE VESICLE; MOUSE; NONHUMAN; PERTUSSIS; PRIORITY JOURNAL; PROTEOMICS;

ACELLULAR VACCINE; BORDETELLA PARAPERTUSSIS; BORDETELLA PERTUSSIS; OMVS; PROTECTION; WHOOPING COUGH;

ANIMALS; BACTERIAL PROTEINS; BORDETELLA INFECTIONS; BORDETELLA PARAPERTUSSIS; BORDETELLA PERTUSSIS; DISEASE MODELS, ANIMAL; EXOSOMES; FEMALE; MICE; MICE, INBRED BALB C; PERTUSSIS VACCINE; PROTEOME; VACCINES, ACELLULAR;

EID: 84885952663     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.08.059     Document Type: Article

References (44)

1. Guiso N. Whooping cough from infants to adults. Bull Acad Natl Med 2008, 192:1437-1449. (discussion 49-52).
2. von Konig C.H., Halperin S., Riffelmann M., Guiso N. Pertussis of adults and infants. Lancet Infect Dis 2002, 2:744-750.
3. Galanis E., King A.S., Varughese P., Halperin S.A. Changing epidemiology and emerging risk groups for pertussis. CMAJ 2006, 174:451-452.
4. WHO Immunization surveillance, assessment and monitoring 2008, http://www.who.int/immunization_monitoring/diseases/pertussis/en/.
5. Watanabe M., Nagai M. Whooping cough due to Bordetella parapertussis: an unresolved problem. Expert Rev Anti Infect Ther 2004, 2:447-454.
6. Heininger U., Stehr K., Schmitt-Grohe S., Lorenz C., Rost R., Christenson P.D., et al. Clinical characteristics of illness caused by Bordetella parapertussis compared with illness caused by Bordetella pertussis. Pediatr Infect Dis J 1994, 13:306-309.
7. Cherry J.D., Seaton B.L. Patterns of Bordetella parapertussis respiratory illnesses: 2008-2010. Clin Infect Dis 2012, 54:534-537.
8. Liese J.G., Renner C., Stojanov S., Belohradsky B.H. Clinical and epidemiological picture of B. pertussis and B. parapertussis infections after introduction of acellular pertussis vaccines. Arch Dis Child 2003, 88:684-687.
9. Mastrantonio P., Stefanelli P., Giuliano M. Bordetella parapertussis infection in children: epidemiology, clinical symptoms, and molecular characteristics of isolates. J Clin Microbiol 1998, 36:999-1002.
10. Bergfors E., Trollfors B., Taranger J., Lagergard T., Sundh V., Zackrisson G. Parapertussis and pertussis: differences and similarities in incidence, clinical course, and antibody responses. Int J Infect Dis 1999, 3:140-146.
11. Stehr K., Cherry J.D., Heininger U., Schmitt-Grohe S., Uberall M., Laussucq S., et al. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine. Pediatrics 1998, 101:1-11.
12. He Q., Viljanen M.K., Arvilommi H., Aittanen B., Mertsola J. Whooping cough caused by Bordetella pertussis and Bordetella parapertussis in an immunized population. JAMA 1998, 280:635-637.
13. Kurova N., Njamkepo E., Brun D., Tseneva G., Guiso N. Monitoring of Bordetella isolates circulating in Saint Petersburg, Russia between 2001 and 2009. Res Microbiol 2010, 161:810-815.
14. Bokhari H., Said F., Syed M.A., Mughal A., Kazi Y.F., Heuvelman K., et al. Whooping cough in Pakistan: Bordetella pertussis vs Bordetella parapertussis in 2005-2009. Scand J Infect Dis 2011, 43:818-820.
15. Long G.H., Karanikas A.T., Harvill E.T., Read A.F., Hudson P.J. Acellular pertussis vaccination facilitates Bordetella parapertussis infection in a rodent model of bordetellosis. Proc Biol Sci 2010, 277:2017-2025.
16. Khelef N., Danve B., Quentin-Millet M.J., Guiso N. Bordetella pertussis and Bordetella parapertussis: two immunologically distinct species. Infect Immun 1993, 61:486-490.
17. Mielcarek N., Debrie A.S., Raze D., Bertout J., Rouanet C., Younes A.B., et al. Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough. PLoS Pathog 2006, 2:e65.
18. WHO-World Health Organization Expert committee on biological standardization WHO/BS/2011.2158 english only 2011, 1-64.
19. Stainer D.W., Scholte M.J. A simple chemically defined medium for the production of phase I Bordetella pertussis. J Gen Microbiol 1970, 63:211-220.
20. Hozbor D., Rodriguez M.E., Fernandez J., Lagares A., Guiso N., Yantorno O. Release of outer membrane vesicles from Bordetella pertussis. Curr Microbiol 1999, 38:273-278.
21. Roberts R., Moreno G., Bottero D., Gaillard M.E., Fingermann M., Graieb A., et al. Outer membrane vesicles as acellular vaccine against pertussis. Vaccine 2008, 26:4639-4646.
22. Asensio C.J., Gaillard M.E., Moreno G., Bottero D., Zurita E., Rumbo M., et al. Outer membrane vesicles obtained from Bordetella pertussis Tohama expressing the lipid A deacylase PagL as a novel acellular vaccine candidate. Vaccine 2010, 29:1649-1656.
23. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
24. Bottero D., Gaillard M.E., Basile L.A., Fritz M., Hozbor D.F. Genotypic and phenotypic characterization of Bordetella pertussis strains used in different vaccine formulations in Latin America. J Appl Microbiol 2012, 112:1266-1276.
25. Bottero D., Gaillard M.E., Fingermann M., Weltman G., Fernandez J., Sisti F., et al. Pulsed-field gel electrophoresis, pertactin, pertussis toxin S1 subunit polymorphisms, and surfaceome analysis of vaccine and clinical Bordetella pertussis strains. Clin Vaccine Immunol 2007, 14:1490-1498.
26. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685.
27. Ferrari G., Garaguso I., Adu-Bobie J., Doro F., Taddei A.R., Biolchi A., et al. Outer membrane vesicles from group B Neisseria meningitidis delta gna33 mutant: proteomic and immunological comparison with detergent-derived outer membrane vesicles. Proteomics 2006, 6:1856-1866.
28. Delvecchio V.G., Connolly J.P., Alefantis T.G., Walz A., Quan M.A., Patra G., et al. Proteomic profiling and identification of immunodominant spore antigens of Bacillus anthracis Bacillus cereus, and Bacillus thuringiensis. Appl Environ Microbiol 2006, 72:6355-6363.
29. Hudson P., Gorton T.S., Papazisi L., Cecchini K., Frasca S., Geary S.J. Identification of a virulence-associated determinant, dihydrolipoamide dehydrogenase (lpd), in Mycoplasma gallisepticum through in vivo screening of transposon mutants. Infect Immun 2006, 74:931-939.
30. Caroff M., Aussel L., Zarrouk H., Martin A., Richards J.C., Therisod H., et al. Structural variability and originality of the Bordetella endotoxins. J Endotoxin Res 2001, 7:63-68.
31. Di Fabio J.L., Caroff M., Karibian D., Richards J.C., Perry M.B. Characterization of the common antigenic lipopolysaccharide O-chains produced by Bordetella bronchiseptica and Bordetella parapertussis. FEMS Microbiol Lett 1992, 76:275-281.
32. Wolfe D.N., Goebel E.M., Bjornstad O.N., Restif O., Harvill E.T. The O antigen enables Bordetella parapertussis to avoid Bordetella pertussis-induced immunity. Infect Immun 2007, 75:4972-4979.
33. Geurtsen J., Banus H.A., Gremmer E.R., Ferguson H., de la Fonteyne-Blankestijn L.J., Vermeulen J.P., et al. Lipopolysaccharide analogs improve efficacy of acellular pertussis vaccine and reduce type I hypersensitivity in mice. Clin Vaccine Immunol 2007, 14:821-829.
34. Wolfe D.N., Buboltz A.M., Harvill E.T. Inefficient Toll-like receptor-4 stimulation enables Bordetella parapertussis to avoid host F immunity. PLoS ONE 2009, 4:e4280.
35. Mielcarek N., Debrie A.S., Raze D., Quatannens J., Engle J., Goldman W.E., et al. Attenuated Bordetella pertussis: new live vaccines for intranasal immunisation. Vaccine 2006, 24(Suppl. 2):S2-S54.
36. Burian V., Kubatova E., Kratochvilova M., Burianova-Vysoka B. New combined alum hydroxide adsorbed diphtheria-tetanus-pertussis-vaccine with parapertussis component I. Reactogenicity and serological efficacy. J Hyg Epidemiol Microbiol Immunol 1970, 14:143-147.
37. Zhang X., Goebel E.M., Rodriguez M.E., Preston A., Harvill E.T. The O antigen is a critical antigen for the development of a protective immune response to Bordetella parapertussis. Infect Immun 2009, 77:5050-5058.
38. Bouchez V., Brun D., Cantinelli T., Dore G., Njamkepo E., Guiso N. First report and detailed characterization of B. pertussis isolates not expressing pertussis toxin or pertactin. Vaccine 2009, 27:6034-6041.
39. Hegerle N., Paris A.S., Brun D., Dore G., Njamkepo E., Guillot S., et al. Evolution of French Bordetella pertussis and Bordetella parapertussis isolates: increase of Bordetellae not expressing pertactin. Clin Microbiol Infect 2012, 18:E340-E346.
40. Mooi F.R., van Loo I.H., van Gent M., He Q., Bart M.J., Heuvelman K.J., et al. Bordetella pertussis strains with increased toxin production associated with pertussis resurgence. Emerg Infect Dis 2009, 15:1206-1213.
41. Moshiri A., Dashtbani-Roozbehani A., Najar Peerayeh S., Siadat S.D. Outer membrane vesicle: a macromolecule with multifunctional activity. Hum Vaccin Immunother 2012, 8:953-955.
42. Komatsu E., Yamaguchi F., Eguchi M., Watanabe M. Protective effects of vaccines against Bordetella parapertussis in a mouse intranasal challenge model. Vaccine 2010, 28:4362-4368.
43. Watanabe M., Nagai M. Reciprocal protective immunity against Bordetella pertussis and Bordetella parapertussis in a murine model of respiratory infection. Infect Immun 2001, 69:6981-6986.
44. Mann P.B., Wolfe D., Latz E., Golenbock D., Preston A., Harvill E.T. Comparative toll-like receptor 4-mediated innate host defense to Bordetella infection. Infect Immun 2005, 73:8144-8152.